A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study

Naunyn-Schmiedeberg's Archives of Pharmacology
S DheinW Klaus


Common antiarrhythmic agents affect ionic membrane channels and thereby alter cellular electrical activity. Since this accounts for the proarrhythmic effects as well we tried to find new substances with different profiles of actions. A new antiarrhythmic peptide, H2N-Gly-Ala-Gly-4 Hyp-Pro-Tyr-CONH2 (AAP 10), was synthetized using the Fmoc-strategy. This peptide was analyzed for its electrophysiological profile of action in normal isolated rabbit hearts perfused according to the Langendorff technique either under control conditions or after induction of a regional ischemia. For this purpose 256 channel epicardial mapping was employed allowing the determination of the timepoints of activation at each electrode thus identifying the origins of epicardial activation (socalled breakthrough-points, BTP). Epicardial spread of activation was then described mathematically by activation vectors which gave direction and velocity of the epicardial activation wave at each electrode. Single heart beats were analyzed under control conditions and under treatment with AAP 10 or under regional ischemia with or without AAP 10-pretreatment (10(-8) mol/l). We calculated the percentage of similar vectors (VEC) with unaltered direction (deviation < or...Continue Reading


Nov 28, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Stefan DheinFriedrich-Wilhelm Mohr
Sep 12, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Joanna JozwiakStefan Dhein
Jun 15, 2007·The Journal of Membrane Biology·Lene Nygaard AxelsenMorten Schak Nielsen
May 26, 1997·European Journal of Pharmacology·A MüllerS Dhein
Sep 10, 2002·Peptides·Stefan Dhein
Jan 30, 2009·Cardiovascular Research·Anja HagenStefan Dhein
Jun 19, 2009·Cardiovascular Research·Sevasti-Maria ChaldoupiHarold V M van Rijen
Apr 6, 2006·Clinical Medicine & Research·Jifen LiGlenn L Radice
Dec 1, 1996·Journal of Cardiovascular Electrophysiology·D J CallansJ F Spear
Jun 18, 2002·Cell Communication & Adhesion·S DheinL Polontchouk
Dec 19, 2003·Cell Communication & Adhesion·Stefan DheinFriedrich-Wilhelm Mohr
Jul 25, 2009·Cell Communication & Adhesion·Xiao-Qing QuanCun-Tai Zhang
Sep 12, 2007·Basic & Clinical Pharmacology & Toxicology·Anne Louise KjølbyeJørgen S Petersen
Nov 19, 2014·Frontiers in Physiology·Stefan DheinFriedrich-Wilhelm Mohr
May 15, 2007·Journal of Cardiovascular Pharmacology and Therapeutics·Jing-quan ZhongPaul Dorian
Jun 4, 2004·Journal of Cardiovascular Pharmacology·Ketil HauganJørgen Søberg Petersen
Mar 13, 2014·FEBS Letters·Christina L GrekGautam S Ghatnekar
Oct 13, 2018·Nature Reviews. Drug Discovery·Dale W Laird, Paul D Lampe
Nov 2, 2014·Cell and Tissue Research·Pier D Lambiase, Andrew Tinker
Sep 22, 2017·Pharmacological Reviews·Luc LeybaertRainer Schulz
Sep 25, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Andrew L Wit, Heather S Duffy
Aug 1, 1997·Journal of Cardiovascular Pharmacology·A SalamehS Dhein
Jun 1, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stephan WengStefan Dhein
Jan 27, 2011·British Journal of Pharmacology·Elke De VuystLuc Leybaert
Jun 19, 2014·Experimental and Therapeutic Medicine·Lei RuanCuntai Zhang
Jan 15, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Dezhi XingJames B Martins
Aug 28, 2020·Biomolecules·Olga M RusieckaBrenda R Kwak
Sep 1, 1997·Medicinal Research Reviews·P MátyusL Virág
Nov 6, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Anne Louise KjølbyeDavid S Rosenbaum
Aug 8, 2021·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Mauricio A RetamalJimmy Stehberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.